Sichenzia Ross Ference LLP Represents INmune Bio Inc. in an $8 Million Initial Public Offering and Listing on the Nasdaq Capital Market
Press Release – New York, NY – February 5, 2019 – Sichenzia Ross Ference (“SRF”), a leading securities and corporate law firm, is pleased to announce that the firm has represented INmune Bio Inc. (INMB), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, in an initial public offering at a price of $8.00 per share resulting in gross proceeds of approximately $8,000,000 and listing on the Nasdaq Capital Market under the ticker symbol INMB.
The SRF team was led by Partners Marc Ross, Thomas Rose and David Manno. View more of Sichenzia Ross Ference’s IPO transactions, here.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock - December 6, 2019
- Sichenzia Ross Ference Trust & Estate Attorneys Quoted in LegalZoom Article - December 6, 2019
- Sichenzia Ross Ference Represents H-Cyte, Inc. in $6.0 Million Private Placement - December 2, 2019